(Press-News.org) A research paper published today (8 February 2024) in The Lancet Oncology demonstrates that the drug enobosarm, a selective androgen receptor modulator which stimulates the male sex hormone receptor has anti-tumour effects in oestrogen receptor positive breast cancer patients.
Lead author Professor Carlo Palmieri from the University of Liverpool and The Clatterbridge Cancer Centre NHS Foundation Trust, said: “These results are very encouraging – we have shown that in advanced/metastatic breast cancer the use of enobosarm can result in clinical benefit, and is the first clinical proof that a non-oestrogen receptor approach with a selective androgen receptor modulator can result in clinical benefit. This builds on the pre-clinical evidence that we published in Nature Medicine.”
For at least 40 years, treatment of this type of breast cancer has focused on directly targeting and inhibiting the activity of the oestrogen receptor. This new study therefore tested a completely different approach.
The orally administered drug enobosarm is a selective androgen receptor modulator, which can stimulate androgen receptor activity in breast cancers. The androgen receptor is a tumour suppressor in oestrogen receptor positive breast cancer.
The multi-site international study led by Dr Beth Overmoyer of the Dana-Farber Cancer Institute of Boston USA evaluated the efficacy and safety of enobosarm in 136 postmenopausal women with locally advanced or metastatic ER-positive, HER2-negative breast cancer (HER2 is a protein called human epidermal growth factor receptor 2, which promotes the growth of cancer cells). Enobosarm was found to have anti-tumour effects, as well as being well tolerated with no significant impact on quality of life.
“These data support further development and assessment of the efficacy of enobosarm and other agents which stimulate the androgen receptor for the treatment of AR-positive, ER-positive, HER2-negative advanced breast cancer.”
The full study A Phase 2 open label randomized study of enobosarm, a novel oral, 1 selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer is available in the Lancet Oncology.
Study shows clinical benefit of new way of treating advanced ER+ breast cancer
ELSE PRESS RELEASES FROM THIS DATE:
Repeat testing for pre-eclampsia does not lead to better outcomes for pregnant women, but a single test is still beneficial
A single test to speed up diagnosis of a serious disease in pregnant women does not need to be repeated, new research has found. Results from the PARROT-2 trial, published today in the Lancet by researchers from King’s College London and funded by Jon Moulton Charitable Trust, Tommy’s Charity and the National Institute for Health and Care Research, has ruled out the need for routine repeat placental growth factor-based testing (PIGF) for all women with suspected pre-eclampsia. PARROT-2 is a large, multi-centre UK trial in 1,252 women ...
Industrial pollution leaves its mark in Mediterranean corals
UCL Press Release Under embargo until Friday 9 February, 00:01 UK time Industrial pollution leaves its mark in Mediterranean corals For the first time, pollutants from burning fossil fuels have been found embedded in corals, offering scientists a potential new tool to track the history of pollution, finds a new study led by UCL researchers. The study, published in the journal Science of the Total Environment, identified carbon particles emitted by burning fossil fuels embedded in the corals of Illa Grossa Bay, off the Columbretes Islands in the Mediterranean Sea. Finding this type of pollution – known as fly-ash or spheroidal carbonaceous particles (SCPs) ...
Urgent call for antitrust measures to safeguard innovation in spatial biology
Recent breakthroughs in spatial biology technology have transformed biomedical research; however, legal disputes are preventing small, innovative companies from advancing new technologies and ideas. Ongoing litigation poses a threat to the progress of even the most promising scientific technologies and the potential discoveries they could enable, according to the authors of the exclusive article titled “Sounding an Alarm Over Spatial Biology,” in Genetic Engineering and Biotechnology News (GEN). Click here to read the article ...
Pre-diabetes gets its due: New $1.2 million award aimed at early intervention and treatment
SAN ANTONIO, Feb. 8, 2024 – More than one out of three people have pre-diabetes, characterized by abnormal blood sugar levels not yet in the diabetes range – and yet associated with significant increases in eye, kidney and neuropathic diseases, and risk of cardiovascular death. Moreover, the number of people with the condition is expected to double by 2030, with prevalence substantially higher in minority populations, including Hispanics. Both pre-diabetes and diabetes are considered global epidemics. As pre-diabetes largely is underdiagnosed and undertreated, ...
Celebrating excellence in anatomy: AAA awards distinguished members
ROCKVILLE, MD – February 8, 2024 – The American Association for Anatomy (AAA) is honored to announce its 2024 awards recipients. Eighteen of the association’s 2,455 members have been selected because they advanced AAA’s values: community, respect, inclusion, integrity, and discovery. The AAA awards program provides over $650,000 in awards, research grants, and scholarships annually. Many recipients go on to achieve significant success in their careers. "We, as anatomy ...
Athira Pharma announces publication in Frontiers in Neuroscience highlighting therapeutic potential of ATH-1105 in amyotrophic lateral sclerosis (ALS)
BOTHELL, WA, Feb. 8, 2024 — Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced publication of research highlighting the neuroprotective and anti-inflammatory effects of ATH-1105 in preclinical models of amyotrophic lateral sclerosis (ALS). The original research article, “ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS,” authored by Berthiaume, A., and Reda, S., et al., was published ...
Sex hormones help gonorrhea fight off antimicrobials and antibiotics
DURHAM, N.C. – You know that package warning that oral birth control won’t prevent STIs? Well in the case of gonorrhea, the sexually transmitted bacterium that causes the disease can use those hormones to help it resist antibiotic attacks. Like many bacteria, this bug, Neisseria gonorrhoeae, is equipped with pumps to push the killing chemicals out of its cells. But what’s unique, according to a Duke and Emory study online this week in Nature Communications, is that the hormones of the human urogenital tract actually allow gonorrhea to make and use more of these pumps to fight intrinsic ...
45 finalists named for the 2024 Hertz Fellowships
The Fannie and John Hertz Foundation today announced 45 finalists for the 2024 Hertz Fellowships in applied science, mathematics and engineering. Selected from more than 860 applicants and representing 21 universities, the finalists advance to a culminating round of interviews for one of the most competitive and coveted doctoral fellowships in the nation. The 2024 class of Hertz Fellows will be announced in May. Since 1963, the Hertz Foundation has granted fellowships empowering the nation’s most promising young ...
How one type of lung cancer can transform into another
Lung tumors called adenocarcinomas sometimes respond to initially effective treatments by transforming into a much more aggressive small cell lung cancer (SCLC) that spreads rapidly and has few options for treatment. Researchers at Weill Cornell Medicine have developed a mouse model that illuminates this problematic process, known as histological transformation. The findings advance the understanding of how mutated genes can trigger cancer evolution and suggest targets for more effective treatments. The researchers, whose results were published ...
Results from South Pole Telescope’s new camera emerge
Argonne is part of a multi-institutional effort to survey the sky for clues about the origins and nature of our universe. For more than five years, scientists at the South Pole Telescope in Antarctica have been observing the sky with an upgraded camera. The extended gaze toward the cosmos is picking up remnant light from the universe’s early formation. Now researchers have analyzed an initial batch of data, publishing details in the journal Physical Review D. The results from this limited dataset hint at even more powerful future insights about the nature of our universe. The telescope at the Amundsen-Scott South Pole Station, which is operated by the National ...